Fat metabolism enzyme DECR1 as castration-resistant prostate cancer target
INDICATION: Prostate cancer
Inhibiting the β oxidation enzyme DECR1 could treat castration-resistant prostate cancer. In biopsies from prostate cancer patients, DECR1 protein levels were higher after the development of resistance to androgen deprivation therapy than before. Analysis of a dataset from the Cancer Genome Atlas also revealed that DECR1 mRNA levels were higher in prostate tumor samples than in normal adjacent tissue, and an association between high DECR1 expression and poor disease-free survival. In human castration-resistant prostate cancer cells, an siRNA against DECR1 increased sensitivity to a ferroptosis activator tool compound and to the androgen receptor antagonist Xtandi enzalutamide. In a mouse model of castration-resistant prostate cancer, tumor-specific DECR1 knockout reduced tumor volume...